Effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting

Table 4 Cytokine levels, T-lymphocyte subsets and Kupffer cell populations at 16 wk

	IL-1(ng/L)	IL-6(ng/L)	TNFα(ng/L)	%CD3+	%CD4+	%CD8+	Ratio CD4+: CD8+	%CD4+ expressing CD25	%CD8+ expressing CD25	Kupffer cells /10 high power fields
Control	22.28 ± 4.39	0	13.6 ± 2.73	74.05 ± 5.49	43.15 ± 3.93	30.9 ± 7.05	1.4	7.96 ± 2.99d	10.62 ± 2.64f	46.26 ± 7.95
Control + rapamycin	25.86 ± 8.71	0	14.84 ± 2.35	73.34 ± 7.73	47.86 ± 8.31	25.48 ± 6.4	1.8	15.54 ± 9.5d	17.9 ± 13.87f	40.3 ± 8.46
PSS	22.23 ± 5.12	0.025 ± 0.045	26.15 ± 45.97	93.4 ± 7.97a	58.96 ± 9.02	34.47 ± 6.59b	1.6	5.38 ± 2.47c	6.05 ± 1.99e	43.45 ± 8.13
PSS + Rapamycin	26.12 ± 6.21	0.011 ± 0.033	15.5 ± 11.83	73.19 ± 5.66	56.78 ± 5.60	18.39 ± 5.73b	3.1	11.38 ± 6.96c	19.10 ± 14.58e	44.95 ± 9.16

%CD3 + T cells PSS vs controls

^bP < 0.001 vs Controls; %CD8+ T cells PSS vs PSS + Rapamycin

^dP < 0.001; %CD4 + CD25 + T cells PSS vs PSS + Rapamycin

^fP < 0.001; %CD4 + CD25 + T cells Control vs Control + Rapamycin ^hP < 0.001; %CD8 + CD25 + T cells PSS vs PSS + Rapamycin ⁱP < 0.001; %CD8 + CD25 + T cells Control vs Control + Rapamycin ^kP < 0.001.